EE200300249A - GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon - Google Patents

GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon

Info

Publication number
EE200300249A
EE200300249A EEP200300249A EEP200300249A EE200300249A EE 200300249 A EE200300249 A EE 200300249A EE P200300249 A EEP200300249 A EE P200300249A EE P200300249 A EEP200300249 A EE P200300249A EE 200300249 A EE200300249 A EE 200300249A
Authority
EE
Estonia
Prior art keywords
combination
reductase inhibitors
aldose reductase
gaba agonists
gaba
Prior art date
Application number
EEP200300249A
Other languages
English (en)
Inventor
Lakshman Mylari Banavara
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300249A publication Critical patent/EE200300249A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300249A 2000-11-30 2001-11-19 GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon EE200300249A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25044800P 2000-11-30 2000-11-30
PCT/IB2001/002214 WO2002043763A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
EE200300249A true EE200300249A (et) 2003-10-15

Family

ID=22947799

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300249A EE200300249A (et) 2000-11-30 2001-11-19 GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon

Country Status (34)

Country Link
US (1) US6720348B2 (et)
EP (1) EP1337272A2 (et)
JP (1) JP2004514700A (et)
KR (1) KR20030059287A (et)
CN (1) CN1477976A (et)
AP (1) AP2001002359A0 (et)
AR (1) AR031432A1 (et)
AU (1) AU2002215160A1 (et)
BG (1) BG107812A (et)
BR (1) BR0115776A (et)
CA (1) CA2430309A1 (et)
CR (1) CR6962A (et)
CZ (1) CZ20031387A3 (et)
DO (1) DOP2001000294A (et)
EA (1) EA200300433A1 (et)
EC (1) ECSP034629A (et)
EE (1) EE200300249A (et)
HR (1) HRP20030419A2 (et)
HU (1) HUP0302555A3 (et)
IL (1) IL155710A0 (et)
IS (1) IS6787A (et)
MA (1) MA26965A1 (et)
MX (1) MXPA03004871A (et)
NO (1) NO20032387L (et)
OA (1) OA12413A (et)
PA (1) PA8534201A1 (et)
PE (1) PE20020598A1 (et)
PL (1) PL365378A1 (et)
SK (1) SK6092003A3 (et)
SV (1) SV2003000752A (et)
TN (1) TNSN01170A1 (et)
UY (1) UY27044A1 (et)
WO (1) WO2002043763A2 (et)
ZA (1) ZA200303340B (et)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (en) 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
WO2003105864A1 (en) * 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
ES2341240T3 (es) * 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
EP1480631B1 (en) * 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators
ATE345120T1 (de) * 2003-03-21 2006-12-15 Dynogen Pharmaceuticals Inc Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MX2008013137A (es) 2006-04-11 2008-10-21 Novartis Ag Compuestos organicos.
JP2010513357A (ja) * 2006-12-22 2010-04-30 ノバルティス アーゲー Ｄｐｐ−ｉｖ阻害剤としての１−アミノメチル−１−フェニル−シクロヘキサン誘導体
EP2139330B1 (en) 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
ES2639019T3 (es) * 2008-09-06 2017-10-25 Bionevia Pharmaceuticals Inc. Nuevo cocristal de colina de epalrestat
EP2654749B1 (en) 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Methods for treating copd
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN107847548B (zh) * 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
CN110769855A (zh) * 2017-04-21 2020-02-07 史蒂文·霍夫曼 用于治疗视网膜病变的组合物和方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138008A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
US4130714A (en) 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
AU530999B2 (en) 1979-06-01 1983-08-04 Wellcome Foundation Limited, The Substituted amino triazines and their use in treatment of cns disorders
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
JPS5740478A (en) 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4791126A (en) 1980-08-22 1988-12-13 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
CA1176269A (en) 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5066659A (en) 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
GB8524663D0 (en) 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
AU602641B2 (en) 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use
DE3769066D1 (de) 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
US4771052A (en) * 1987-02-05 1988-09-13 Hoechst-Roussel Pharmaceuticals, Inc. Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents
GB8801037D0 (en) 1988-01-18 1988-02-17 Plessey Co Ltd Improvements relating to fuel supply systems
US5252572A (en) * 1988-02-03 1993-10-12 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4980357A (en) 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5037831A (en) 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JP2789134B2 (ja) * 1992-09-28 1998-08-20 ファイザー・インク． 糖尿病の合併症を制御する置換ピリミジン類
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6350769B1 (en) * 1999-02-24 2002-02-26 The Regents Of The University Of California Gaba alpha receptors mediate inhibition of T cell responses
DE60009777T2 (de) * 1999-04-01 2004-08-19 Pfizer Products Inc., Groton Verbindung für Behandlung und Vorsorge bei Diabetes
AU782344C (en) * 1999-04-08 2006-08-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders

Also Published As

Publication number Publication date
HRP20030419A2 (en) 2004-08-31
WO2002043763A2 (en) 2002-06-06
OA12413A (en) 2004-09-30
IS6787A (is) 2003-04-14
JP2004514700A (ja) 2004-05-20
CA2430309A1 (en) 2002-06-06
HUP0302555A2 (hu) 2003-11-28
US20020077319A1 (en) 2002-06-20
HUP0302555A3 (en) 2005-06-28
CZ20031387A3 (cs) 2004-04-14
SK6092003A3 (en) 2004-07-07
US6720348B2 (en) 2004-04-13
UY27044A1 (es) 2002-07-31
NO20032387D0 (no) 2003-05-27
EP1337272A2 (en) 2003-08-27
AR031432A1 (es) 2003-09-24
ECSP034629A (es) 2003-07-25
MXPA03004871A (es) 2003-08-19
BR0115776A (pt) 2004-01-13
NO20032387L (no) 2003-05-27
AP2001002359A0 (en) 2001-12-31
KR20030059287A (ko) 2003-07-07
SV2003000752A (es) 2003-01-13
CR6962A (es) 2004-02-02
IL155710A0 (en) 2003-11-23
CN1477976A (zh) 2004-02-25
TNSN01170A1 (fr) 2005-11-10
BG107812A (bg) 2004-02-27
DOP2001000294A (es) 2002-08-30
ZA200303340B (en) 2004-04-30
EA200300433A1 (ru) 2003-10-30
PL365378A1 (en) 2005-01-10
PA8534201A1 (es) 2002-10-24
PE20020598A1 (es) 2002-07-08
MA26965A1 (fr) 2004-12-20
AU2002215160A1 (en) 2002-06-11
WO2002043763A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
EE200300249A (et) GABA agonistide ja aldoosreduktaasi inhibiitoritekombinatsioon
EE200300248A (et) GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon
EE200300470A (et) Aldoosreduktaasi püridasinooninhibiitorid
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE200300361A (et) PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
ATE376999T1 (de) Hydroxamate-derivate als deacetylase inhibitoren
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
EE200200426A (et) PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
NO20030406D0 (no) Ikke-steroidale inflammasjonshemmere
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
ITMI20021391A1 (it) Nitroderivati di inibitori della cicloossigenasi-2
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
IL157935A0 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
SE0004239D0 (sv) New use of an inhibitor
AR027946A1 (es) Uso de los inhibidores il-18